Rallybio Holds Annual Shareholder Meeting

• Rallybio shareholders approved share issuance for the proposed Avenzo merger at the November 4, 2026, annual meeting.
• Shareholders authorized a 1-for-2 to 1-for-9 reverse stock split and an increase in authorized common shares from 200,000,000 to 500,000,000.
• They also approved renaming the company Avenzo Therapeutics and elected four Class II directors.
• The 2026 Equity Incentive Plan and Employee Stock Purchase Plan won approval, with effectiveness contingent on merger completion.
• Shareholders ratified Deloitte & Touche as auditor for fiscal 2026; the proposed adjournment was unnecessary and not submitted for approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-447550), on November 04, 2026, and is solely responsible for the information contained therein.